Analytical Data
-
Gene name
Promotilin/MLN
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N- His-GST & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P12872
-
Expression Region
26-115aa
-
Molecular Weight
45.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Promotilin, also known as MLN (motilin-like neuropeptide), is a peptide hormone primarily produced in the gastrointestinal tract, playing a crucial role in regulating gut motility. Its discovery stems from the need to understand gastrointestinal disorders, particularly those associated with motility dysfunction, such as gastroparesis and irritable bowel syndrome. Research has shown that promotilin stimulates gastric contractions and promotes coordinated motor activity in the digestive system, acting through specific receptors in the gastrointestinal tract. The recombinant production of promotilin has garnered significant attention in biomedical research, as it offers a tool for studying its physiological effects and potential therapeutic applications. By utilizing recombinant protein technology, researchers are able to produce pure and active forms of promotilin, allowing for detailed investigations into its biological functions and mechanisms of action. Furthermore, understanding the signaling pathways activated by promotilin could lead to new treatment strategies for motility-related disorders, enhancing the quality of life for affected patients. As studies continue to explore the pharmacological potential of this peptide, both in vitro and in vivo, the promise of recombinant promotilin as a therapeutic agent remains an exciting area of investigation in gastrointestinal research.
